Opinion|Videos|November 6, 2024
Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis
Key Takeaways
- FcRn inhibitors have distinct dosing and administration protocols, necessitating careful consideration by clinicians for optimal therapeutic outcomes.
- Adherence to specific dosing guidelines is crucial to maximize efficacy and minimize adverse effects in patients receiving FcRn inhibitors.
Panelists discuss how they approach and potentially adapt the dosing and administration regimens of approved and investigational FcRn inhibitors in their myasthenia gravis patients, considering the prescribed guidelines and individual patient needs.
Advertisement
Video content above is prompted by the following:
- Approved and investigational FcRn inhibitors have different dosing/administration regimens.
- Do you follow these dosing regimens in your patients?
Advertisement
Related to this article
The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.
Amy Waldman, MD, Medical Director of the Leukodystrophy Center at Children's Hospital of Philadelphia, discusses zilganersen's mechanism, safety profile, clinical considerations, and what the first-ever approval for Alexander disease means for the broader leukodystrophy field.
Results recently published from the phase 2 HIMALAYA trial reported that SAR443820 did not slow functional decline, and was associated with more adverse events and treatment discontinuations in patients with ALS.
Alit Stark-Inbar, PhD, Chief Scientific Officer of Theranica, writes about migraine prevention beyond lifestyle changes, highlighting the role of neuromodulation and other evidence-based treatments in long-term management.
A new study reported that tremor and myoclonus affected nearly 7 in 10 patients with chronic inflammatory demyelinating polyneuropathy, with immunotherapy and beta-blockers showing potential benefit for symptom improvement.
Michela Leocadi, PhD, research fellow at UCL Queen Square Institute of Neurology, discussed new longitudinal data showing early functional connectivity changes in HD gene carriers years before clinical motor diagnosis.
In a phase 4 randomized controlled trial, opicapone failed to demonstrate statistical superiority over placebo for reducing fluctuation-related pain in patients living with Parkinson disease.
Robert Bowser, PhD, chief scientific officer at Barrow Neurological Institute, recaps his ALS Nexus presentation on TDP-43 biology, the emerging therapeutic landscape, and how cryptic peptide biomarkers could reshape ALS clinical trial design.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Unmet Needs in CIDP
2
Topline Phase 2 ADDRESS-LC Data Show Subgroup Benefit for Bezisterim in Long COVID
3
Previewing Advancements in Hypersomnia Diagnosis and Treatment
4
Brain Network Changes Appear Decades Before Motor Symptoms in Huntington Disease
5